chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Extreme chills, shivering, 102 fever that lasted 6 hours, severe fatigue, moderate headache, severe body aches, severe nausea  .
Pt was admitted for acute encephalopathy of unknown etiology.  He also had acute respiratory failure due to COVID pneumonia.
I experienced after my 3rd dose I started to feel unwell and went to get tested for COVID-19 on 01-21-2022. My result was positive, experienced constant headaches the pain was strong, I could not sleep at night, had hallucinations with my eyes open and heard voices. On week earlier my high blood pressure went up and had a lot of headaches. My blood pressure was also high. Then one week later I also began again to experience constant headaches and change in voice. I got very scared due to my symptoms. I also got a temperature, cough, sore throat. I was prescribed asthma medication but do not remember the name. I was positive for COVID for three weeks and I still continue to have hallucinations, feel very fatigue and when I am ambulate I feel out of breath and my chest hurts. Today I still have fatigue and the voices in my head, not as frequent but still are present.
Miscarried the morning after I received the vaccine. I have been pregnant prior with no miscarriage and conceived immediately after the miscarriage. Pregnancy is early but with no sign of impending miscarriage.
Patient did not experience any adverse events, treatments, outcomes, or reactions to todays vaccination.  Patient had 2 Pfizer (Maroon Cap) and came to clinic to receive her 3rd dose to finish her series. Her mother requested Moderna (Pink Label) for her last dose. Vaccinator administer the vaccine (Moderna Infant AR9236B) as requested. After the patient and her mother left the clinic, Vaccinator asked the Medical Lead a clarifying question regarding protocols at which point Vaccinator realized the patient was supposed to received a Pfizer ( Maroon)  since switching primary doses is not allowed. Moderna was administered as 3rd dose instead of Pfizer.
Information has been received from a physician concerning a 19-20 year old female who was vaccinated with the first 0.5 ml dose of GARDASIL (no lot number was provided) over a year ago (approximately 2008). Subsequently the patient experienced "neuropathy" and "winging of scapula". The patient discontinued after the first dose. She partially recovered and had gone to physical therapy. Additional information has been requested.
I experienced fever, chills, fatigue, muscle aches and headache after 9 hours from receiving my second dose of Moderna COVID-19 vaccine. The pain was so severe I almost went to the ED and had to take off work the following day. My temperature was as high as 102.4 degrees Fahrenheit. I took acetaminophen but this did not help the pain. However, this only lasted less than 24 hours and I made a complete recovery. I have not experienced any issues since.
pt recv vax FEB98 & 8-10 days post vax pt exp a local inj site rash;the rash was red raised wheal, non-tender;
Strong headache with inflammation of the left side of head.  After first doses headache lasted for 2 weeks and inflammation was light-and moderated. However after second doses, it has been already three weeks with the headache and the inflammation has been increasing. now it is more pronounced and extended. pain has been increasing as well.
red rash over top third of arm in which the vaccine was administered. started as a small localized reaction right away but spread over course of next few days. has not yet resolved. no pain associated, but some itching. patient will follow up with physician if rash does not resolve in next day or so, she states
Very sore arm (much worse than the first shot a month earlier). I woke up on March 27 (day after being vaccinated for my second shot) feeling like I was coming down with the flu, with aches and pains, and fatigue. No fever. I took ibuprofen and felt better but I had a general "under the weather" feeling until the following day. But for five days afterwards, I had to take a nap in the late afternoon and felt generally more tired. Also, my elbow has been hurting in my vaccinated arm for the past week (I never have issues with that elbow, though it could be coincidence and unrelated to the vaccine).
HIVES ALL OVER BODY WITH INTENSE ITCHING. CONTINUED INTO THE NEXT DAY. RECEIVED INJECTION OF ANTIHISTAMINE AND STERIOD.  RECEIVED STEROID DOSE PACK AND CONTINUED TO TAKE ANTIHISTAMINE AROUND THE CLOCK EVERY 4 HOURS.
100°F temperature for 24 hours; tired feeling; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (100°F temperature for 24 hours) and FATIGUE (tired feeling) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 058E21A) for COVID-19 vaccination.     It was reported that the Patient did not have any allergy. It was also reported that patient never had Covid-19 test.     On 25-Oct-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PYREXIA (100°F temperature for 24 hours) and FATIGUE (tired feeling). At the time of the report, PYREXIA (100°F temperature for 24 hours) and FATIGUE (tired feeling) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On an unknown date, Body temperature: 100 (High) 100 degree Fahrenheit temperature for 24 hours.         No concomitant and treatment drug was reported.   This case was linked to MOD-2022-544267, MOD-2022-544448, MOD-2022-544443, MOD-2022-544280 (Patient Link).   Reporter did not allow further contact
This spontaneous report was received from a Medical Assistant referring to two unspecified patients of unknown age and gender. The patients' pertinent medical history, concurrent conditions and drug reactions/allergies were not provided. Since 24-APR-2018, the patients had been administered improperly stored doses of VARIVAX lot # N022980, expiration date on 23-AUG-2019, lot #N027001, expiration date on 28-SEP-2019, for prophylaxis (strength, dose and route of administration were not reported). An sterile diluent (MERCK) was used to reconstitute vaccines. Vaccines were improperly stored at a temperature between 6°F to 14°F (8.5°F) for 38 minutes. No previous temperature excursions neither adverse effects were reported. The call was because of a data logger. The outcome was supported. Follow-up information received from medical assistant on 08-MAY-2018. The patient was identified to be a 4-year-old male patient. On 24-APR-2018, the patient was vaccinated with improperly stored dose of VARIVAX from lot N027001. This is one of the two reports linked via same reporter link. Sender's Comments: US-009507513-805USA004343.
Myalgia, Arthralgia, chills, fever of 100F at peak, night sweats Narrative:
pt recv vax; shortly p/ 2nd vax, devel rash which persisted at time of rpt;
Fatigue, Moderate body aches Intermittent Fever  first 24hours Headache Red & soreness around injection site. Persisted for 48hours. Took Motrin, hot showers & herbal teas. Bed rest
Developed some rashes, HCP discards shingles; This case was reported by a physician via call center representative and described the occurrence of rash in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced rash. On an unknown date, the outcome of the rash was unknown.   It was unknown if the reporter considered the rash to be related to Shingrix.     Linked case(s) involving the same patient:  US2022AMR057922   Additional Information: GSK Receipt Date: 30-March-2022 Reporter's Comments: Physician reported that a patient developed some rashes  after being administered with 2 shingrix doses in 2019.  The reporter discarded that the rashes were because the shingles disease, but the patient requested revaccination with shingrix. The reporter was not consulted to follow up, callback attempted but not successful. The reporter consented to follow-up.; Sender's Comments:  US-GLAXOSMITHKLINE-US2022AMR057922:Same reporter
On day of injection patient advises she was sore and had site pain. Site was warm to touch, first day after injection patient had shoulder joint pain and tenderness. Patient took OTC ADVIL. Second day after injection site was red, hot to touch, tender, and had shoulder joint pain.
A report has been received from a Health Professional concerning a female subject, who had been receiving nasal FLUMIST Quadrivalent. FLUMIST Quadrivalent started on an unknown date. The patient experienced multiple patients received FLUMIST Quadrivalent and tested positive for Flu A. The outcome of the event of multiple patients tested positive for Flu A is unknown. The report was considered to be non-serious.
Rash on arm at injection site , hot, spreading slowly (now palm size) looks similar to CoVID Arm pictures online
Pt experienced (per parents input) a lot of "gut" symptoms-diarrhea, abd. pain. Mother and father state recent dx. of "celiac" disease. Pt saw MD for evaluation-put on steroids.
She fainted, employee stated she saw her seize, EMS called and she was transfered. Intial reactiom 15:37 pm.
No adverse event; 113 Bivalent doses administered after the BUD to patients 12 and up.; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (113 Bivalent doses administered after the BUD to patients 12 and up.) and NO ADVERSE EVENT (No adverse event) in a 50-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7148B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 20-Oct-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 20-Oct-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (113 Bivalent doses administered after the BUD to patients 12 and up.). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (113 Bivalent doses administered after the BUD to patients 12 and up.) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (113 Bivalent doses administered after the BUD to patients 12 and up.).    Patient ID was reported. Concomitant medications details were not reported by the reporter. It was reported that 60 doses received to several patient from Lot AS7148B. It was unknown if the patient received any other vaccines in the 4 weeks prior to COVID-19 vaccine. Treatment details were not reported by the reporter.
3/3/06 baby started to scream and could not be consoled. would not eat, approx 8pm baby vomited once profusely, then again smaller amount, child arrested, very hypotonic eyes rolled to back of head, no fever, transported to hospital via ambulance. 6/20/06 Medical records received from hospital which reveal patient experienced altered mental status, vomiting & lethargy same day as vaccination received and was admitted to hospital for overnight observation.  W/U results were WNL & was d/c to be followed by PCP/ss
Patient described heart racing, feeling "weak", and dizziness about 3 hours after taking her first typhoid pill.  She felt better within about 6 hours.  No treatment needed.
Covid-19 vaccine related pneumonitis; This is a literature report.  A 72-year-old female patient received BNT162b2 (BNT162B2), as dose 3 (booster); single (Batch/Lot number: unknown) for covid-19 immunization. The patient's relevant medical history included: "ED" (unspecified if ongoing). The patient took concomitant medications. Vaccination history included: Covid-19 vaccine (DOSE 1; MANUFACTURER UNKNOWN), for COVID-19 Immunization; Covid-19 vaccine (DOSE 2; MANUFACTURER UNKNOWN), for COVID-19 Immunization. The following information was reported: PNEUMONITIS (hospitalization, medically significant, life threatening), 2 days after the suspect product(s) administration, outcome "recovered", described as "Covid-19 vaccine related pneumonitis". The patient was hospitalized for pneumonitis (hospitalization duration: 5 day(s)). The event "covid-19 vaccine related pneumonitis" required emergency room visit. The patient underwent the following laboratory tests and procedures: Antinuclear antibody: positive; Bronchoalveolar lavage: WBC 204 /cumm with lymphocytic predominance; Bronchoscopy: revealed diffuse erythematous with copious, thick, whitish mucus plugging airways; Computerised tomogram thorax: revealed bil ground-glass opacities; Culture: positive, notes: for candida albicans in 1/2 pooled sample; Silver stain: negative, notes: for P. jirovecii; Microbiology test: negative; Serology test: negative; White blood cell count: 204 /mm3. Therapeutic measures were taken as a result of pneumonitis.; Sender's Comments: As there is limited information in the case provided, the causal association between the reported event "PNEUMONITIS" and the suspect drug cannot be excluded. The case will be reassessed once new information is available.   The impact of this report on the benefit/risk profile of the Pfizer drug is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to Regulatory Authorities, Ethics Committees, and Investigators, as appropriate.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 61-year-old male patient received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown), in left arm for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "recovering" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: Treatment of COVID-19. Therapeutic measures were taken as a result of drug ineffective, covid-19. Clinical course: The patient did not receive any medication in two weeks. The patient has received Paxlovid for the treatment of COVID-19 from 19Jul2022 to 24Jul2022. The patient has experienced covid-19 rebound on 29Jul2022 and was recovering, the patient did not receive any treatment.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
small rash at injection site fever, body aches severe nerve pain (burning) in entire body started 4 hours after injection and still continues 10 days later with no sign of ending
Information has been received from a healthcare worker referring to a patient of unknown age and gender. Information about concurrent conditions, medical history and concomitant medication was not provided. On 03-AUG-2015, the patient was vaccinated with one dose of improperly stored (Oka/Merck) VARIVAX (lot # was reported as L004653, expire date 11-FEB-2017, (dose, dose# and route not provided) (incorrect product storage). No adverse effect was reported.
not feeling good; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program. The reporter is the patient.  A female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: FEELING ABNORMAL (non-serious), outcome "unknown", described as "not feeling good".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Migraine; Lethargy; Fuzzy memory; Fever at the injection site; Swelling at the injection site/swollen to softball size; Gets up and lays back down; Headache/head exploding at top; Bodyache; This spontaneous case was reported by a consumer and describes the occurrence of MIGRAINE (Migraine), LETHARGY (Lethargy), MEMORY IMPAIRMENT (Fuzzy memory), VACCINATION SITE WARMTH (Fever at the injection site) and VACCINATION SITE SWELLING (Swelling at the injection site/swollen to softball size) in a 70-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 048A21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Diabetes, Cholesterol and Blood pressure abnormal. Concomitant products included LOSARTAN for Blood pressure abnormal, EZETIMIBE for Cholesterol, METFORMIN HYDROCHLORIDE (METFORMIN ER) for Diabetes.    On 12-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Mar-2021, the patient experienced MIGRAINE (Migraine), LETHARGY (Lethargy), VACCINATION SITE WARMTH (Fever at the injection site), VACCINATION SITE SWELLING (Swelling at the injection site/swollen to softball size), FATIGUE (Gets up and lays back down), HEADACHE (Headache/head exploding at top) and MYALGIA (Bodyache). 13-Mar-2021, the patient experienced MEMORY IMPAIRMENT (Fuzzy memory). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency and DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at an unspecified dose and frequency. At the time of the report, MIGRAINE (Migraine), LETHARGY (Lethargy), MEMORY IMPAIRMENT (Fuzzy memory), VACCINATION SITE WARMTH (Fever at the injection site), VACCINATION SITE SWELLING (Swelling at the injection site/swollen to softball size), FATIGUE (Gets up and lays back down), HEADACHE (Headache/head exploding at top) and MYALGIA (Bodyache) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Treatment details included usage of steroid cream and ice.  It was reported that Patient had no improvements with symptoms despite treatments.
Patient calling to report she received second COVID-19 vaccine 3 days ago. Patient is having difficulty functioning since vaccination. Patient is fatigued, body aches. Patient states that she is having a "hard time getting around" due to exhaustion. Able to stand and walk without difficulty. Able to do some of normal housework. No fevers. PCP performed labs - D-dimer elevated, troponin negative, EKG normal. Sent to ED for concern of PE. CTA-PE negative. D/C'd home in stable condition.
Diluent used to reconstitute Proquad for patient on 03/03/23 expired on 03/02/2023. Called Merck vaccines medical line  Diluent for use is supported. No recommendation for revaccination. Vaccine does not need to be repeated. Diluent has been removed from our supply.
First noticed left arm  (injected arm) - top of shoulder to elbow was swollen the next morning. Nausea. Face periodically feels flush.
she states that an expired dose was administered to 1 patient or maybe 2 patients; No Adverse Event; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (she states that an expired dose was administered to 1 patient or maybe 2 patients) and NO ADVERSE EVENT (No Adverse Event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced EXPIRED PRODUCT ADMINISTERED (she states that an expired dose was administered to 1 patient or maybe 2 patients) and NO ADVERSE EVENT (No Adverse Event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (she states that an expired dose was administered to 1 patient or maybe 2 patients) and NO ADVERSE EVENT (No Adverse Event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No Adverse Event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (she states that an expired dose was administered to 1 patient or maybe 2 patients).    No concomitant medication information was reported. It was Unknown patient receive any other vaccines in the 4 weeks prior to COVID-19 vaccine. No treatment medication information was reported.
Left arm swelled up after receiving 2nd Moderna's booster dose; Left arm red up to elbow after receiving 2nd Moderna's booster dose; Inflammation; This spontaneous case was reported by a consumer and describes the occurrence of PERIPHERAL SWELLING (Left arm swelled up after receiving 2nd Moderna's booster dose), ERYTHEMA (Left arm red up to elbow after receiving 2nd Moderna's booster dose) and INFLAMMATION (Inflammation) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PERIPHERAL SWELLING (Left arm swelled up after receiving 2nd Moderna's booster dose), ERYTHEMA (Left arm red up to elbow after receiving 2nd Moderna's booster dose) and INFLAMMATION (Inflammation). At the time of the report, PERIPHERAL SWELLING (Left arm swelled up after receiving 2nd Moderna's booster dose), ERYTHEMA (Left arm red up to elbow after receiving 2nd Moderna's booster dose) and INFLAMMATION (Inflammation) outcome was unknown.            No concomitant medications were reported. The patient had no allergies. Treatment included Antibiotic to stop Inflammation which worked.   This case was linked to MOD-2022-541363 (Patient Link).
Notified by high school that student had a "delayed reaction" several hours after H1N1 shot that was given at school student went to hospital and was transferred to another hospital. Chief complaint was numbness and weakness of legs.
On the evening of Friday 4/2/2021 around 9:30 PM, I was experiencing what felt like heartburn. It got better before I went to bed. At around 9:00 AM on Saturday 4/3/2021, I was awakened by intense pain and pressure that felt like the worst heartburn I'd ever experienced. After OTC heartburn treatments didn't help, at around 11:00 AM I went to the local ER where I was initially diagnosed as having a heart attack. After being given some baby aspirin and a nitro tablet, I started feeling better and was airlifted immediately to a nearby cardiology unit at another hospital. A heart catheterization and EKGs determined that I had not had a heart attack, but instead had takotsubo cardiomyopathy. I was admitted into the cardiac ICU overnight for observation, transferred to a non-critical room the next day (4/4/2021), and released on Monday 4/5/2021.
Td administered by nurse 09/08/2005. Seen MD 09/10/2005, erythema and tenderness left upper arm diagnosis cellulitis. Must follow up left arm is much better. Keflex and Benadryl prescribed.